

AMENDMENTS TO THE CLAIMS

Claim 1 (Currently Amended): An immunogenic composition comprising ~~an effective amount of~~ a hydrophobic complex consisting essentially of proteosomes, at least one ~~non-detoxified antigenic lipopolysaccharide or glycolipid~~ and a pharmaceutically acceptable carrier.

Claims 2-3 (Cancelled)

Claim 4 (Previously Amended): The immunogenic composition of claim 1, wherein the proteosomes are isolated from *N. meningitidis*.

Claim 5 (Cancelled)

Claim 6 (Currently Amended): A vaccine comprising ~~an effective amount of~~ a hydrophobic complex consisting essentially of proteosomes, at least one ~~non-detoxified antigenic lipopolysaccharide or glycolipid~~ and a pharmaceutically acceptable carrier.

1
D Claim 7 (Currently Amended): A method for ~~providing enhanced~~ inducing immunogenicity comprising administering the immunogenic composition of ~~any one of claims 1-4~~ 1 or 4 or the vaccine of claim 6 to a subject orally or intranasally to ~~impart enhanced~~ induce immunity.

Claim 8 (Currently Amended): A method of ~~achieving~~ inducing immunity by administering the immunogenic composition of ~~any one of claims 1-4~~ 1 or 4 or the vaccine of claim 6 to a subject orally or intranasally to ~~impart~~ induce immunity.

Claim 9 (Currently Amended): A method of ~~achieving~~ inducing immunity according to claim 8 wherein the immunity is to Ggram-negative bacterial infection.

Claim 10 (Currently Amended): A method of ~~achieving~~ inducing immunity according to claim 9 wherein the Ggram-negative bacterial infection is a Neisserial infection.

RECEIVED

JUN 05 2003

TECH CENTER 1600/2900

Claim 11 (Currently Amended): A method of ~~achieving~~ inducing immunity according to claim 10 wherein the infection is a gonococcal infection.

Claim 12 (Currently Amended): A method of ~~achieving~~ inducing immunity according to claim 10 wherein the infection is a meningococcal infection.

Claims 13-15 (Cancelled)

Claim 16 (Currently Amended): A method of ~~achieving~~ inducing immunity according to claim 8 by administering the immunogenic composition or the vaccine to mucosal surfaces selected from the group consisting of respiratory, gastrointestinal, vaginal, nasal, rectal and oral mucosa.

Claim 17 (New): The immunogenic composition of claim 1, wherein the glycolipid is a ganglioside.

Claim 18 (New): The immunogenic composition of claim 1, wherein the proteosomes are isolated from *Neisseria*.
